Importantly, the observed enrichment was not confounded by a gene's status as a known driver (a source of up-weighting in the INQUISIT pipeline), since the enrichment was observed even when the genes which were nominated as INQUISIT level 1 on the basis of being known BC driver genes (CASZ1, CCNE1, CREBBP, and NF1) were downgraded to INQUISIT level 2. This evidence concerns the gene CASZ1 and breast cancer.